Programme Guide

Friday, June 21, 2024

11:00 a.m. - 12:00 p.m. Registration 11:30 a.m. - 12:50 p.m. Buffet Lunch

Lunch Symposium (Not Accredited)

12:00 - 12:40 p.m. Presentation 12:40 - 12:50 p.m. Discussion

Main Programme (Accredited)

01:00 - 01:10 p.m. Introduction and Welcome

Dr. Nathan Lamond Co-Chair, ACOG

Session I – GU Cancer Chair: Dr. Elizabeth Faour

01:10 - 01:40 p.m. Update on the systemic therapy options for metastatic prostate cancer

01:40 - 01:50 p.m. Discussion

Dr. Sohaib Al-Asaaed

At the conclusion of the event, participants will be able to:

1. Describe the overall landscape of metastatic prostate cancer management

2. Provide an overview of the evolution of prostate cancer treatments

3. Review recent developments in the management of metastatic prostate cancer

01:50 - 02:20 p.m. Diagnostic PSMA PET scans (Virtual)

02:20 - 02:30 p.m. Discussion

Dr. Cynthia Menard

02:30 - 03:00 p.m. Radionuclide PSMA therapy for patients with advanced prostate

cancer

03:00 - 03:10 p.m. Discussion

Dr. Jean-Mathieu Beauregard

At the conclusion of the event, participants will be able to:

- 1. Describe the principles of PSMA-RLT
- 2. Review the evidence about the clinical benefits of PSMA-RLT
- 3. List the potential toxicities and side effects of PSMA-RLT
- 4. Recognize the current and emerging indications of PSMA-RLT in the management of advanced prostate cancer

03:10 - 03:30 p.m. Break/Visit Exhibits

03:30 - 04:00 p.m. Androgen Deprivation Therapy (ADT) for patients with advanced

prostate cancer

04:00 - 04:10 p.m. Discussion

Dr. Matt Acker

At the conclusion of the event, participants will be able to:

1. Review the available hormonal therapies for prostate cancer treatment

- 2. Summarize the major adverse events associated with conventional androgen deprivation therapy (ADT)
- 3. Review the evidence-based strategies to mitigate the adverse events associated with ADT in men with prostate cancer

04:10 - 05:00 p.m. Case Based Panel – Panel Discussion of Genitourinary Cancer Cases

Facilitator - Dr. Myuran Thana

Medical Oncology – Dr. Sohaib Al-Asaaed **Radiation Oncology –** Dr. Robert Thompson

Urologist – Dr. Matt Acker

Nuclear Medicine Specialist -- Dr. Jean-Mathieu Beauregard

At the conclusion of the event participants will be able to:

1. Summarize the role of the multidisciplinary team in the management of Genitourinary Cancers

2. Explore practical case-based options for management of genitourinary cancers.

7:00 p.m. Cash Bar

7:30 p.m. Dinner -- Waterfront Warehouse, 1549 Lower Water Street

Saturday, June 22, 2024

07:30 - 08:50 a.m. Buffet Breakfast

Breakfast Symposium (Not Accredited)

08:00 - 08:40 a.m.

08:40 - 08:50 a.m. Discussion

Main Programme (Accredited)

Chair: Dr. Ceilidah MacPhail

Session II – General Oncology Topics

09:00 - 09:30 a.m. The importance of exercise in cancer prevention and treatment

09:30 - 09:40 a.m. Discussion

Dr. Scott Grandy

At the conclusion of the event, participants will be able to:

- 1. Identify the benefits of exercise across the cancer continuum.
- 2. Recall exercise guidelines for those living with and beyond cancer.
- 3. Recognize key patient/medical variables that influence exercise prescription.
- 4. Name exercise resources for those living with and beyond cancer.

09:40 - 10:10 a.m. No Fat Shame: Where We Get it Wrong and How We Can do Better

10:10 - 10:20 a.m. Discussion

Dr. Ali Zentner

At the conclusion of the event, participants will be able to:

1. Examine the prevalence and presence of weight bias in medicine.

- 2. Explore the origins of weight bias in medicine and the effect it has had on our patients and on our system.
- 3. Establish some "rules of engagement" to mitigate and combat weight bias in our practices and in our world.

10:20 - 10:50 a.m. **Genetics Discussion on Molecular Testing**

10:50 - 11:00 a.m. Discussion

Erin Chamberlain, MSc, CCGC

At the conclusion of the event, participants will be able to

- 1. Review genetics terminology and concepts relating to hereditary cancer
- 2. Identify factors that are relevant to a hereditary cancer assessment
- 3. Describe the role of genetic counseling in the context of these assessments
- 4. Discuss the benefits and considerations of genetic testing
- 5. Define the possible results from testing and the implications for patients/families

11:00 - 11:20 a.m. **Break/Visit Exhibits**

11:20 - 11:55 a.m. **CAMO Lecture (Virtual)**

Choosing Wisely updated Oncology Recommendations

11:55 - 12:10 p.m. Discussion

Dr. Safia Karim

At the conclusion of the event, participants will be able to:

- 1. Review the history of the Choosing Wisely Oncology Campaign in Canada
- 2. Review the updated Choosing Wisely Oncology Recommendations
- 3. Describe the future vision and direction of the CW Oncology Campaign in Canada

12:10 - 12:40 p.m. **Global Oncology**

12:40 - 12:50 p.m. Discussion

Dr. Bishal Gyawali

At the conclusion of the event, participants will be able to:

- 1. Define the concept of cancer ground shot and apply the concept to addressing issues in global
- 2. Collaborate with colleagues from LMICs to start an academic career in global oncology
- 3. Describe the challenges in global cancer care, and how one is able to contribute to addressing these challenges

Closing Remarks 12:50 - 01:00 p.m.

Dr. Erin Powell, Co-Chair, ACOG